| Oct 1 |
NeuroBo Pharmaceuticals to Participate in Investor Conferences in October
|
| Sep 30 |
We're A Little Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Rate
|
| Sep 30 |
NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
|
| Sep 3 |
NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 21 |
NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24…
|
| Aug 15 |
NeuroBo Pharmaceuticals GAAP EPS of -$1.85
|
| Aug 14 |
NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 14 |
NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial
|
| Aug 13 |
NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
|
| Aug 6 |
NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity
|
